Get the Stockscreener App
815.34
0.47%
3.0732
Regeneron Pharmaceuticals Inc stock is traded at $815.34, with a volume of 370.09K.
It is up +0.47% in the last 24 hours and up +16.04% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$812.27
Open:
$805.81
24h Volume:
370.09K
Relative Volume:
0.38
Market Cap:
$85.79B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
19.52
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+5.73%
1M Performance:
+16.04%
6M Performance:
+48.99%
1Y Performance:
+11.24%
1-Day Range:
$801.35
$816.82
1-Week Range:
$753.20
$816.76
52-Week Range:
$476.49
$816.76
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
816.25 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.08 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.53 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.03 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
171.39 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Noesis Capital Mangement Corp Has $11.90 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KLP Kapitalforvaltning AS Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
MassMutual Private Wealth & Trust FSB Buys 1,267 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Retinopathy Market to Witness Remarkable Growth With - openPR.com
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) - Yahoo Finance
Regeneron Just Moved From Underperform To BuyHere's Why - Benzinga
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (CORRECTED) - Benzinga
Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. - Barron's
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline - Seeking Alpha
Regeneron Science Talent Search: 33 Long Island students named semifinalists - Newsday
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts - Proactive financial news
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Finviz
Regeneron Pharma gains as BofA upgrades rating - TradingView — Track All Markets
Why Regeneron (REGN) Stock Is Trading Up Today - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 By Investing.com - Investing.com India
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Bank of America - MarketBeat
Analyst Upgrade: Regeneron Pharmaceuticals (REGN) Rating Boosted to Buy | REGN Stock News - GuruFocus
21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know - Benzinga
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Merit Financial Group LLC Has $1.05 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to hit US$ 7.44 Billion by 2033 | Top - openPR.com
Will Regeneron Pharmaceuticals Inc. stock maintain dividend yield2026 world cup usa national team round of 32 key players low block defense group prediction preview - Улправда
Regeneron Upgraded From Underperform to Buy – Here’s the Reason - Bitget
The Truth About Regeneron Pharm: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Looking at the Latest Short Interest Trends for Regeneron Pharmaceuticals Inc - Bitget
Peering Into Regeneron Pharmaceuticals Inc's Recent Short Interest - Benzinga
How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors - simplywall.st
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth - TradingView — Track All Markets
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson - sharewise.com
Regeneron Pharmaceuticals Inc RGO Stock Analysis and ForecastStock Screening Results & Big Gains Low Budget - earlytimes.in
Intellia Stock Declines Around 55% in 3 Months: Here's Why - TradingView — Track All Markets
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 - The Globe and Mail
Regeneron Pharmaceuticals Inc Stock Analysis and ForecastAnalyst Downgrades & Small Budget Capital Gains - earlytimes.in
Allspring Global Investments Holdings LLC Sells 6,253 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating the Biotech Giant’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - simplywall.st
Regeneron (REGN) Valuation Check After Japan Clears Dupixent for Pediatric Severe Asthma Expansion - Yahoo Finance
Regeneron Shares Maintain Momentum as Key Catalysts Align - AD HOC NEWS
Financiere des Professionnels Fonds d investissement inc. Acquires Shares of 3,171 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades - TIKR.com
Brookwood Investment Group LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week - MSN
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 - The Manila Times
Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host ... - Caledonian Record
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):